한글목차

무통성 갑상선염 시장 규모는 2025년 29억 6,000만 달러에서 2026-2034년 CAGR 6.54%로 성장하여 2034년에는 52억 4,000만 달러에 이를 것으로 예측됩니다.

무통성 갑상선염 시장은 갑상선 질환에 대한 인식이 높아지고 효과적인 관리 전략이 필요함에 따라 성장할 것으로 예측됩니다. 무통성 갑상선염은 갑상선에 통증이 없는 염증이 특징이며, 일시적인 갑상선 기능 항진증을 거쳐 갑상선 기능 저하증을 유발할 수 있습니다. 이 질환에 대한 의료진과 환자들의 인식이 높아짐에 따라 진단 도구와 치료 옵션에 대한 수요가 증가할 것으로 예측됩니다. 이 시장은 갑상선 기능 검사, 영상 진단법, 코르티코스테로이드 및 갑상선 호르몬 대체요법 등 다양한 치료 옵션을 포함한 광범위한 제품을 포괄하고 있습니다.

기술 혁신은 무통성 갑상선염 시장을 크게 형성하고 있으며, 진단 기술의 발전으로 갑상선 평가의 정확성과 신속성이 향상되고 있습니다. 초음파 검사, 핵의학 검사 등 첨단 영상진단 기술의 발달로 무증상 갑상선염의 진단 정확도가 향상되어 다른 갑상선 질환과의 감별이 용이해졌습니다. 또한, 원격 의료 및 원격 모니터링 솔루션의 도입으로 갑상선 질환의 적시 진단 및 관리가 촉진되어 환자가 적절한 치료를 받을 수 있는 환경이 조성되고 있습니다. 시장이 계속 진화하는 가운데, 진단 및 치료 솔루션 강화를 위한 연구개발을 우선시하는 기업이 경쟁 우위를 점할 가능성이 높습니다.

또한, 무통성 갑상선염 시장은 갑상선 관리의 근거 중심적 관행을 장려하는 의료기관의 임상 가이드라인과 권고사항의 영향을 점점 더 많이 받고 있습니다. 의료 시스템이 갑상선 질환의 진단 및 치료에 있어 표준화된 프로토콜을 채택함에 따라, 신뢰할 수 있고 효과적인 솔루션에 대한 수요는 계속 증가할 것입니다. 이러한 추세는 새로운 치료 접근법을 찾고 기존 치료법을 개선하기 위한 연구 이니셔티브에 대한 투자를 촉진하고 있습니다. 환자 중심의 치료와 삶의 질에 대한 관심이 높아짐에 따라 무통성 갑상선염의 효과적인 관리 전략에 대한 필요성이 확대되고 있으며, 임상적 요구에 부합하는 제품을 제공하는 기업이 이 중요한 시장에서 성공할 수 있는 위치에 서게 될 것입니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 무통성 갑상선염 시장 : 진단 검사별

제5장 세계의 무통성 갑상선염 시장 : 치료법별

제6장 세계의 무통성 갑상선염 시장 : 환자 유형별

제7장 세계의 무통성 갑상선염 시장 : 지역별

제8장 경쟁 구도

제9장 기업 개요

영문목차

The Silent Thyroiditis Market size is expected to reach USD 5.24 Billion in 2034 from USD 2.96 Billion (2025) growing at a CAGR of 6.54% during 2026-2034.

The Silent Thyroiditis market is set for growth, driven by the increasing recognition of thyroid disorders and the need for effective management strategies. Silent thyroiditis, characterized by painless inflammation of the thyroid gland, can lead to transient hyperthyroidism followed by hypothyroidism. As awareness of this condition grows among healthcare providers and patients, the demand for diagnostic tools and therapeutic options is expected to rise. The market encompasses a range of products, including thyroid function tests, imaging modalities, and treatment options such as corticosteroids and thyroid hormone replacement therapy.

Technological advancements are significantly shaping the Silent Thyroiditis market, with innovations in diagnostic technologies enhancing the accuracy and speed of thyroid assessments. The development of advanced imaging techniques, such as ultrasound and nuclear medicine scans, is improving the ability to diagnose silent thyroiditis and differentiate it from other thyroid disorders. Additionally, the integration of telemedicine and remote monitoring solutions is facilitating timely diagnosis and management of thyroid conditions, ensuring that patients receive appropriate care. As the market continues to evolve, companies that prioritize research and development to enhance their diagnostic and therapeutic offerings will likely gain a competitive edge.

Moreover, the Silent Thyroiditis market is increasingly influenced by clinical guidelines and recommendations from healthcare organizations that promote evidence-based practices in thyroid management. As healthcare systems adopt standardized protocols for diagnosing and treating thyroid disorders, the demand for reliable and effective solutions will continue to rise. This trend is driving investment in research initiatives aimed at exploring novel treatment approaches and improving existing therapies. As the focus on patient-centered care and quality of life grows, the need for effective management strategies for silent thyroiditis will expand, positioning companies that align their offerings with clinical needs for success in this vital market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Diagnostic Test

• Thyroid Function Tests
• Thyroid Antibodies Tests
• Ultrasound
• Biopsy

By Treatment

• Antiinflammatory Medications
• Anticepressants
• Hormone Replacement Therapy
• Radioactive lodine Treatment

By Patient Type

• Adults
• Children
• Pregnant Women
• Postpartum Women

COMPANIES PROFILED

• AstraZeneca pic, GiaxoSmilhiine plc, Bayer AG, Sanofi SA, Novo Nordisk AS, Boeing Ingelheim GmbH, Novartis AG, bof Laboralores Inc, Pizer Inc, Merck Co Inc, Ef Lily and Company, Amgen Inc, Johnson Johnson, Teva Phamaceutial Industries Ld

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SILENT THYROIDITIS MARKET: BY DIAGNOSTIC TEST 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Diagnostic Test
• 4.2. Thyroid Function Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Thyroid Antibodies Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Ultrasound Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SILENT THYROIDITIS MARKET: BY TREATMENT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment
• 5.2. Antiinflammatory Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Anticepressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Hormone Replacement Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Radioactive lodine Treatment Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SILENT THYROIDITIS MARKET: BY PATIENT TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Patient Type
• 6.2. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Children Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Pregnant Women Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Postpartum Women Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SILENT THYROIDITIS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Diagnostic Test
  • 7.2.2 By Treatment
  • 7.2.3 By Patient Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Diagnostic Test
  • 7.3.2 By Treatment
  • 7.3.3 By Patient Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Diagnostic Test
  • 7.4.2 By Treatment
  • 7.4.3 By Patient Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Diagnostic Test
  • 7.5.2 By Treatment
  • 7.5.3 By Patient Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Diagnostic Test
  • 7.6.2 By Treatment
  • 7.6.3 By Patient Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SILENT THYROIDITIS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AstraZeneca Pic
  • 9.2.2 GiaxoSmilhiine Plc
  • 9.2.3 Bayer AG
  • 9.2.4 Sanofi S.A
  • 9.2.5 Novo Nordisk A'S
  • 9.2.6 Boeing Ingelheim GmbH
  • 9.2.7 Novartis AG
  • 9.2.8 Bof Laboralores Inc
  • 9.2.9 Pizer Inc
  • 9.2.10 Merck & Co Inc
  • 9.2.11 Ef Lily And Company
  • 9.2.12 Amgen Inc
  • 9.2.13 Johnson & Johnson
  • 9.2.14 Teva Phamaceutial Industries Ld